To illustrate the promise of this technology, LyTONs were developed to target Menin (MEN1), a promising clinical target involved in transcriptional regulation over cellular differentiation and proliferation in leukemias.23 The MEN1 LyTONs resulted in a dramatic protein-level knockdown following treatment. This evidence concerns the gene MEN1 and leukemia.